107202-39-1

Basic information

• Product Name: N-BOC-L-CYCLOHEXYLGLYCINOL
• Synonyms: BOC-CHG-OL;N-T-BOC-L-CYCLOHEXYLGLYCINOL;N-T-BUTOXYCARBONYL-L-CYCLOHEXYLGLYCINOL;N-BOC-L-CYCLOHEXYLGLYCINOL;N-Boc-L-2-aMino-2-cyclohexyl-ethanol;N-Boc-L-cyclohexylglycinol;(S)-tert-butyl (1-cyclohexyl-2-hydroxyethyl)carbamate;(S)-2-(Boc-amino)-2-cyclohexylethanol
• CAS NO: 107202-39-1
• Molecular Formula: C₁₃H₂₅NO₃
• Molecular Weight: 243.34
• Product Categories: Amino Acid Derivatives;Amino Alcohols;Peptide Synthesis
• Mol File: 107202-39-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 83-87 °C(lit.)
• Boiling Point: 371.2 ºC at 760 mmHg
• Flash Point: 178.3 ºC
• Appearance: /
• Density: 1.037
• Vapor Pressure: 5.05E-07mmHg at 25°C
• Refractive Index: 1.482
• Storage Temp.: Store at 0-5°C
• PKA: 12.07±0.46(Predicted)
• CAS DataBase Reference: N-BOC-L-CYCLOHEXYLGLYCINOL(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-L-CYCLOHEXYLGLYCINOL(107202-39-1)
• EPA Substance Registry System: N-BOC-L-CYCLOHEXYLGLYCINOL(107202-39-1)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 107202-39-1(Hazardous Substances Data)

Usage

General Description

N-Boc-L-cyclohexylglycinol, also known as N-tert-butoxycarbonyl-L-cyclohexylglycinol, is a chemical compound with the molecular formula C14H25NO4. It is a white to off-white crystalline powder that is soluble in organic solvents. N-Boc-L-cyclohexylglycinol is often used as a building block in the synthesis of various pharmaceuticals and other organic compounds. It is a derivative of cyclohexylglycine, an amino acid that has been investigated for its potential use in the treatment of neurological and psychiatric disorders. Additionally, N-Boc-L-cyclohexylglycinol has been studied for its potential use as a chiral auxiliary in asymmetric catalysis and organic synthesis. Overall, this compound has various potential applications in the field of medicinal chemistry and organic synthesis.

InChI:InChI=1/C13H25NO3/c1-13(2,3)17-12(16)14-11(9-15)10-7-5-4-6-8-10/h10-11,15H,4-9H2,1-3H3,(H,14,16)/t11-/m1/s1

Upstream product

• 54512-75-3 1-bromo-5-chloropentane 
• 109183-71-3 N-(tert-butoxycarbonyl)-L-cyclohexylglycine 
• 543-27-1 isobutyl chloroformate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 845714-30-9 (S)-2-amino-2-cyclohexylethan -1-ol 
• 155905-75-2 [(R)-1-(1-Benzenesulfonyl-cyclohexyl)-2-(tetrahydro-pyran-2-yloxy)-ethyl]-carbamic acid tert-butyl ester 
• 116611-45-1 (2R)-2-t-butoxycarbonylamino-3-phenylsulfonyl-1-(2-tetrahydropyranyloxy)propane 
• 14328-51-9 (2S)-amino(cyclohexyl)ethanoic acid 
• 107202-38-0 tert-butyl (S)-(methoxycarbonyl)(cyclohexyl)methylcarbamate 

Downstream Products

• 1429925-31-4 2-[(4S)-7-(3-chlorophenyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl]-N-{(1S)-1-cyclohexyl-2-[4-(dimethylamino)piperidin-1-yl]ethyl}acetamide 
• 1429925-20-1 N-[(1S)-1-cyclohexyl-2-(4-methylpiperazin-1-yl)ethyl]-2-[(4S)-7-(2-fluoropyridin-4-yl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl]acetamide 
• 1429925-34-7 2-[(4S)-7-(5-chloro-2-fluorophenyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl]-N-[(1S)-1-cyclohexyl-2-(4-methylpiperazin-1-yl)ethyl]acetamide 
• 1429925-16-5 N-[(1S)-1-cyclohexyl-2-(4-methylpiperazin-1-yl)ethyl]-2-[(4S)-7-(3,4-difluorophenyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl]acetamide 
• 1438882-87-1 (S)-1-cyclohexyl-2-(2-pyridin-4-yl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yloxy)ethylamine 
• 1072147-06-8 C₁₆H₂₇NO₃ 
• 944144-74-5 C₁₅H₂₉NO₃ 
• 732282-83-6 (S)-3-(N-tert-butoxycarbonyl-2-amino-2-cyclohexylethyl)-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methyluracil 
• 732282-74-5 (S)-5-bromo-3-(N-tert-butoxycarbonyl-2-amino-2-cyclohexylethyl)-1-(2,6-difluorobenzyl)-6-methyluracil 
• 109183-71-3 N-(tert-butoxycarbonyl)-L-cyclohexylglycine 

Relevant articles and documents

Immunoregulator

The invention discloses an immune regulator, in particular to a compound for inhibiting IL - 17A and application of the compound as an immunomodulator in preparation of medicines. The invention discloses a compound shown in formula I. The application of t

Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings

Extensive SAR studies of the P3 capping group led to the discovery of a series of potent inhibitors with sultam and cyclic sulfonyl urea moieties as the P3 capping. The bicyclic thiophene-sultam or phenyl-sultam cappings were selected for further SAR development. Modification at the P3 side chain determined that the tert-butyl group was the best choice at that position. Optimization of P1 residue significantly improved potency and selectivity. The combination of optimal moieties at all positions led to the discovery of compound 33. This compound had the best overall profile in potency and PK profile: excellent Ki* of 5.3 nM and activity in replicon (EC90) of 80 nM, extremely high selectivity of 6100, and a good rat PO AUC of 1.43 μM h.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.